Endologix to Host Physician Conference Call to Discuss Nellix Technology on November 11, 2010

IRVINE, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that the Company will host a physician conference call on Thursday, November 11, 2010 at 1:00 p.m. ET / 10:00 a.m. PT. to provide further information on the EVAR technology developed by Nellix Inc.  Endologix announced a definitive agreement to acquire Nellix on October 27, 2010.

The call will be hosted by John McDermott, Endologix President and Chief Executive Officer, and will include a presentation by Dr. Andrew Holden, Associate Professor and Director of Interventional Radiology at Auckland City Hospital in Auckland, New Zealand.  Dr. Holden will provide an overview of his experience with the Nellix technology and will be available for a question and answer session.  Accompanying presentation slides will be posted on the investor relations section of Endologix's Web site at http://investor.endologix.com/ before the conference call begins.  Additional information about Nellix's technology can be found on the investor relations section of Endologix's Web site by clicking on the section titled "Nellix Technology."

The dial-in numbers for the conference call are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers.  A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at www.endologix.com.  After the live Web cast, the call will remain available on Endologix's Web site, www.endologix.com, through December 31, 2010.  In addition, a telephonic replay of the call will be available until November 18, 2010.  The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers.  Please use the replay pin number 360348.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders.  The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA).  AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.  Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture.  The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.  Additional information can be found on Endologix's Web site at www.endologix.com.

Additional Information About the Proposed Transaction and Where to Find It

This press release may be deemed soliciting material relating to the proposed transaction between Endologix and Nellix.  In connection with the proposed transaction, Endologix will file a proxy statement and other materials with the Securities and Exchange Commission.  Investors and security holders are advised to read the proxy statement and these other materials when they become available because they will contain important information about Endologix and the proposed transaction.  Investors and security holders may obtain a free copy of the proxy statement (when available) and other documents filed by Endologix with the Securities and Exchange Commission at the Securities and Exchange Commission's Web site at www.sec.gov.

The proxy statement and other relevant documents are also available for free on Endologix's website at www.endologix.com under "Investor Relations/Financial Information/SEC Filings" or by directing such request to Investor Relations, Endologix, Inc., (949) 595-7283.

Endologix and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Endologix in connection with the proposed transaction.  Information concerning the interests of Endologix's participants in the solicitation is set forth in Endologix's proxy statements and Annual Reports on Form 10-K, previously filed with the Securities and Exchange Commission, and in the proxy statement relating to the proposed transaction when it becomes available.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements relating to the potential benefits of Endologix's proposed acquisition of Nellix, including expected operating synergies, the strength of Nellix's technology and the potential for long-term growth and expanded market share. Endologix intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on the current estimates and assumptions of Endologix's management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the forward-looking statements made in this press release. Important factors that could cause actual results to differ materially from forward-looking statements include, but are not limited to, risks relating to the ability to consummate the proposed acquisition, the ability to successfully integrate Nellix's  technology with its current and future product offerings, the scope of potential use of Nellix's technology, the ability to obtain and maintain required U.S. Food and Drug Administration and other regulatory approvals of Nellix's technology, the scope and validity of intellectual property rights applicable to Nellix's technology, the ability to build a direct sales and marketing organization in Europe, competition from other companies, the ability to successfully market and sell its products, plans for developing new products and entering new markets and additional factors that may affect future results which are detailed in Endologix's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2010, and in Endologix's other periodic reports filed with the Securities and Exchange Commission. Endologix undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

SOURCE Endologix, Inc.